Moderna Inc.’s experimental flu shot made with mRNA technology will be reviewed by a Food and Drug Administration advisory ...

May 21 () - Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another ‌part ...

On May 6, 2026, Moderna’s board amended its bylaws to require Securities Act of 1933 lawsuits be filed exclusively in US ...

After getting slapped with a surprise refuse-to-file letter signed by former CBER Director Vinay Prasad, Moderna’s flu ...

May 21 (Reuters) - The U.S. FDA said on Thursday it would hold a meeting of outside experts next month to review Moderna's ...

Moderna stock climbed after the deadly hantavirus outbreak drew investors' attention to the company's ongoing infectious ...

Moderna’s experimental mRNA flu shot will be reviewed by a Food and Drug Administration (FDA) advisory panel next month, a ...

Moderna (NASDAQ:MRNA) is back in the headlines after ripping 63.17% higher year to date on a surprise Q1 revenue triple and ...

Moderna’s mRNA flu vaccine gave more protection against illness than the standard flu shot in a phase 3 clinical trial, according to published results.

Moderna's early hantavirus vaccine research has boosted stock price, reflecting market interest. The vaccine is in initial stages, with potential public health benefits but years from availability.

Shares of Moderna ( MRNA) were up nearly 7% in recent trading, following a 12% jump Friday, after Bloomberg reported the ...

Moderna shares jump as it reveals it has been researching vaccines against hantaviruses - The hantavirus outbreak on the MV ...